Licensed rights and other intangible assets (Tables)

12 Months Ended

Dec. 31, 2022

Goodwill And Intangible Assets Disclosure [Abstract]

Summary of Information about License Rights and Other Intangible Assets, Net

The following provides information about our license rights and other intangible assets, net (in thousands):

	As of December 31, 2022						As of December 31, 2021
	Gross						Gross
	Carrying		Accumulated				Carrying		Accumulated
	Amount		Amortization		Net		Amount		Amortization		Net
Intangible assets    subject to amortization:
Hormone therapy drug patents	$	6,225	$	1,598	$	4,627	$	5,834	$	1,042	$	4,792
Hormone therapy drug patents applied    and pending approval		1,995		—		1,995		2,020		—		2,020
Intangible assets    subject to amortization		8,220		1,598		6,622		7,854		1,042		6,812
Intangible assets not subject to amortization:
Trademarks/trade name rights		321		—		321		332		—		332
Intangible assets, net	$	8,541	$	1,598	$	6,943	$	8,186	$	1,042	$	7,144

Summary of Intangible Assets Subject To Amortization Is Expected To Be Amortized

Our intangible assets subject to amortization are expected to be amortized as follows (in thousands):

Year ending December 31,
2023	$	337
2024		439
2025		438
2026		438
2027		438
Thereafter		2,537
Total	$	4,627